Australian oncology-focused biotech Kazia Therapeutics (Nasdaq: KZIA) has reported preclinical and translational data supporting NDL2, a protein degrader designed to eliminate nuclear PD-L1, an ...
News Medical on MSN
Study offers a practical strategy to enhance effectiveness of immune checkpoint inhibitors
Cancer immunotherapy has transformed modern oncology by harnessing body's own immune system to combat malignant disease.
Kazia stated that in murine triple-negative breast cancer preclinical models, NDL2 reduced primary tumor volume by 49% as ...
Cancer immunotherapy has been a game-changer, but many tumors still find ways to slip past the immune system. New research ...
Cancer immunotherapy has transformed modern oncology by harnessing the body's own immune system to combat malignant disease.
The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology to include ...
A proposed model illustrating how tumor cells release PD-L1-containing small extracellular vesicles (sEVs) that suppress ...
The Sydney-based oncology company revealed that NDL2 is designed to eliminate nuclear PD-L1, which Kazia identified as a previously unrecognized driver of immunotherapy resistance and metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results